Chronic hepatitis C genotype 2 or 3 shor
β
Ricardo Moreno-Otero; MarΓa Trapero; JosΓ© A. Moreno-Monteagudo
π
Article
π
2008
π
John Wiley and Sons
π
English
β 45 KB
Dalgard et al. 1 reported interesting data on 14 versus 24 weeks of combination therapy in patients with hepatitis C virus (HCV) genotype 2 or 3, and they concluded that it is rational to treat those patients with rapid virological response (RVR) for only 14 weeks. Adequate treatment duration is gen